Related Experiment Videos
Recombinant factor VIIa improves coagulopathy caused by liver failure
Jeffrey B Brown1, Karan M Emerick, Deborah L Brown
1Department of Gastroenterology, Hepatology, and Nutrition, Children's Memorial Hospital, Northwestern University, Feinberg School of Medicine, Chicago, IL 60614, USA.
Journal of Pediatric Gastroenterology and Nutrition
|September 10, 2003
Summary
Recombinant activated factor VII (rFVIIa) effectively corrects coagulopathy in children with liver failure, normalizing prothrombin times and reducing bleeding complications. This therapy offers sustained hemostasis when traditional treatments fail.
Area of Science:
- Hepatology
- Hematology
- Pediatric Critical Care
Background:
- Coagulopathy is a significant complication in patients with liver failure.
- Traditional therapies for coagulopathy in liver failure often have limited efficacy.
Purpose of the Study:
- To identify indications for recombinant activated factor VII (rFVIIa) use in pediatric liver failure.
- To evaluate the treatment outcomes of rFVIIa in children with liver failure.
Main Methods:
- Retrospective review of pediatric patients with liver failure treated with rFVIIa.
- Comparison of prothrombin times (PT) before and after rFVIIa therapy.
Main Results:
- rFVIIa therapy rapidly normalized PT in pediatric liver failure patients.
- Sustained improvement in hemostasis was observed for up to 3 days.
- rFVIIa treatment led to clinical improvement in bleeding complications and potentially improved fluid balance without thrombotic events.
Conclusions:
- rFVIIa is effective in normalizing PT and improving hemostasis in pediatric liver failure.
- rFVIIa provides a valuable therapeutic option for coagulopathy refractory to fresh frozen plasma.
- rFVIIa therapy is associated with reduced clinical bleeding and improved fluid balance in this patient population.